Response to “Linear IgA bullous dermatosis protracted by vancomycin-loaded bone cement”

Gurung, Puran; Yaakub, A.; Patel, Priya; Ramaiya, Arjun; Tan, E.

doi:10.1016/j.jdcr.2019.07.017

Cited by 2 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…58 Vancomycin-impregnated devices used in arthroplasty (e.g., vancomycin-impregnated cement spacer or bone cement) have also been reported to trigger LAD. 59,60 The development of vancomycin-induced LAD does not appear to be dose-dependent. 61…”

Section: Drug As Soci Ationmentioning

confidence: 99%

“…Ocular involvement T A B L E 3 Non-exhaustive list of drugs reported in DILAD. 49,54,[58][59][60][61][62][63][64] Antibiotics: vancomycin, trimethoprim-sulfamethoxazole, penicillins, cephalosporins may present as sterile conjunctivitis. Fever may occur.…”

Section: Neonates and Childrenmentioning

confidence: 99%

“…Most cases of vancomycin‐induced LAD have been consistently associated with its intravenous administration 58 . Vancomycin‐impregnated devices used in arthroplasty (e.g., vancomycin‐impregnated cement spacer or bone cement) have also been reported to trigger LAD 59,60 . The development of vancomycin‐induced LAD does not appear to be dose‐dependent 61 …”

Section: Drug Associationmentioning

confidence: 99%

See 2 more Smart Citations

S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology

Caux,

Patsatsi,

Karakioulaki

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

IntroductionLinear IgA dermatosis (LAD) is a rare subepidermal autoimmune bullous disease (AIBD) defined by predominant or exclusive immune deposits of immunoglobulin A at the basement membrane zone of skin or mucous membranes. This disorder is a rare, clinically and immunologically heterogeneous disease occurring both in children and in adults. The aim of this project is to present the main clinical features of LAD, to propose a diagnostic algorithm and provide management guidelines based primarily on experts' opinion because of the lack of large methodologically sound clinical studies.MethodsThese guidelines were initiated by the European Academy of Dermatology and Venereology (EADV) Task Force Autoimmune Bullous Diseases (AIBD). To achieve a broad consensus for these S2k consensus‐based guidelines, a total of 29 experts from different countries, both European and non‐European, including dermatologists, paediatric dermatologists and paediatricians were invited. All members of the guidelines committee agreed to develop consensus‐based (S2k) guidelines. Prior to a first virtual consensus meeting, each of the invited authors elaborated a section of the present guidelines focusing on a selected topic, based on the relevant literature. All drafts were circulated among members of the writing group, and recommendations were discussed and voted during two hybrid consensus meetings.ResultsThe guidelines summarizes evidence‐based and expert opinion‐based recommendations (S2 level) on the diagnosis and treatment of LAD.ConclusionThese guidelines will support dermatologists to improve their knowledge on the diagnosis and management of LAD.

show abstract